Moreover, it was discovered that specifically silencing the expression of URB1-AS1 with N-acetylgalactosamine (GalNAc)-small interfering URB1-AS1 effectively potentiated the sensitivity of HCC cells to sorafenib in an in vivo tumour model. Here, URB1 is linked to neoplasm.